Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3811MR)

This product GTTS-WQ3811MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3811MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13141MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ15481MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3818MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ15519MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ1431MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ7691MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ2802MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ3877MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW